Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-28T17:39:10.706Z Has data issue: false hasContentIssue false
  • English
  • Français

Preliminary dosimetric evaluation of 90Y-BPAMD as a potential agent for bone marrow ablative therapy

Published online by Cambridge University Press:  23 October 2018

Ali Rabiei ,
Hassan Yousefnia ,
Samaneh Zolghadri  and
Mojtaba Shamsaei
Ali Rabiei
Affiliation:
Energy Engineering and Physics Department, Amir Kabir University of Technology, Tehran, Iran
Hassan Yousefnia
Affiliation:
Material and Nuclear Fuel Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran
Samaneh Zolghadri*
Affiliation:
Material and Nuclear Fuel Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran
Mojtaba Shamsaei
Affiliation:
Energy Engineering and Physics Department, Amir Kabir University of Technology, Tehran, Iran
*
Author for correspondence: Samaneh Zolghadri, E-mail: szolghadri@aeoi.org.ir
Get access Rights & Permissions [Opens in a new window]

Abstract

Aim

Bone-seeking radiopharmaceuticals are potential therapeutic tools for bone marrow ablation in patients with multiple myeloma. In this procedure, estimation of radiation absorbed dose received by the target and non-target organs is one of the most important parameters that should be undertaken. This research revolves around the absorbed dose to human organs after 90Y-BPAMD injection.

Materials and methods

90Y-(4-{[(bis(phosphonomethyl))carbamoyl]methyl}-7,10-bis(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl) acetic acid (90Y-BPAMD) complex was successfully prepared under optimised conditions. The human absorbed dose of the complex was estimated based on the biodistribution data on rats using the radiation-absorbed dose-assessment resource method. The target to non-target absorbed dose ratios for the complex was compared with the ratios for 166Ho-DOTMP, as the main radiopharmaceutical for bone marrow ablation.

Results

As expected, the highest amounts of absorbed dose were observed in the bone surface and the bone marrow with 2·52 and 2·29 mGy/MBq, respectively. The red marrow to the most organ absorbed dose ratios for 90Y-BPAMD are much higher than the ratios for 166Ho-DOTMP.

Findings

90Y-BPAMD has interesting characteristics compared with 166Ho-DOTMP and can be considered as a high potential agent for bone marrow ablative therapy of the patient with multiple myeloma.

Keywords

absorbed dosebone marrow ablationBPAMD166Ho-DOTMPmultiple myelomaYttrium-90
Type
Original Article
Information
Journal of Radiotherapy in Practice , Volume 18 , Issue 1 , March 2019 , pp. 70 - 74
Copyright
© Cambridge University Press 2018 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Cite this article: Rabiei A, Yousefnia H, Zolghadri S, Shamsaei M. (2019) Preliminary dosimetric evaluation of 90Y-BPAMD as a potential agent for bone marrow ablative therapy. Journal of Radiotherapy in Practice18: 70–74. doi: 10.1017/S146039691800047X

References

1. Alexanian, R, Dimopoulos, M. The treatment of multiple myeloma. N Engl J Med 1994; 330: 484–489.Google Scholar
2. Nishiyama, Y, Tateishi, U, Shizukuishi, K et al. Role of 18F-fluoride PET/CT in the assessment of multiple myeloma: initial experience. Ann Nucl Med 2013; 27: 78–83.Google Scholar
3. Cascini, G L, Cuccurullo, V, Tamburrini, O et al. Nuclear medicine in multiple myeloma more than diagnosis. Nucl Med Rev Cent East Eur 2010; 13: 32–38.Google Scholar
4. Cavo, M, Gobbi, M, Tura, S. Peptichemio in multiple myeloma. (Preliminary results). Haematologica 1981; 66: 208–215.Google Scholar
5. http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-treating-by-stage. Accessed on 31st August 2018.Google Scholar
6. Bayouth, J E, Macey, D J, Kasi, L P et al. Pharmacokinetics, dosimetry and toxicity of Holmium-166-DOTMP for bone marrow ablation in multiple myeloma. J Nucl Med 1995; 36: 730–737.Google Scholar
7. Breitz, H B, Wendt, R E, Stabin, M S et al. 166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy. J Nucl Med 2006; 47: 534–542.Google Scholar
8. Wiesmann, A, Einsele, H, Kanz, L, Dohmen, B M. Complete remission after myeloablation with bone-seeking 186Re-HEDP and high-dose melphalan followed by autologous stem cell transplantation in a patient with chemorefractory multiple myeloma. Bone Marrow Transplant 2005; 36: 89–90.Google Scholar
9. Rabie, A, Enayati, R, Yousefnia, H et al. Preparation, quality control and biodistribution assessment of 153Sm-BPAMD as a novel agent for bone pain palliation therapy. Ann Nucl Med 2015; 29: 870–876.Google Scholar
10. Fellnera, M, Biesalski, B, Bausbacher, N et al. (68)Ga-BPAMD: PET-imaging of bone metastases with a generator based positron emitter. Nucl Med Biol 2012; 39: 993–999.Google Scholar
11. Fellner, M, Baum, R P, Kubícek, V et al. PET/CT imaging of osteoblastic bone metastases with (68)Ga-bisphosphonates: first human study. Eur J Nucl Med Mol Imaging 2010; 37: 834.Google Scholar
12. Yousefnia, H, Zolghadri, S, Sadeghi, H R et al. Preparation and biological assessment of 177Lu-BPAMD as a high potential agent for bone pain palliation therapy: comparison with 177Lu-EDTMP. J Radioanal Nucl Chem 2016; 307: 1243–1251.Google Scholar
13. Macfarlane, D J, Durrant, S, Bartlett, M L et al. 153Sm EDTMP for bone marrow ablation prior to stem cell transplantation for haematological malignancies. Nucl Med Commun 2002; 23: 1099–1106.Google Scholar
14. Vanhemert, F J, Sloof, G W, Schimmel, K J M et al. Radiopharmaceutical management of 90Y/111In labeled antibodies: shielding and quantification during preparation and administration. Ann Nucl Med 2006; 20: 575–581.Google Scholar
15. Horovitz, C T. Biochemistry of Scandium and Yttrium, Part 2: Biochemistry and Applications. New York: Springer, 2000.Google Scholar
16. Ogawa, K, Kawashima, H, Shiba, K et al. Development of [90Y]DOTA-conjugated bisphosphonate for treatment of painful bone metastases. Nucl Med Biol 2009; 36: 129–135.Google Scholar
17. Környei, J, Antalffy, M, Baranyai, L. Opportunities in bone and joint therapy in the mirror of radiopharmaceuticals. www.cigota.rs/sites/default/files/abstract11.pdf. Accessed on 31st August 2018.Google Scholar
18. Rabiei, A, Shamsaei, M, Yousefnia, H et al. Development and biological evaluation of 90Y-BPAMD as a novel bone seeking therapeutic agent. Radiochimica Acta 2016; 104: 727–734.Google Scholar
19. Pandey, U, Dhami, P S, Jagesia, P et al. Extraction paper chromatography technique for the radionuclidic purity evaluation of 90Y for clinical use. Anal Chem 2008; 80: 801–807.Google Scholar
20. Yousefnia, H, Zolghadri, S, Jalilian, A R, Naseri, Z. Preliminary absorbed dose evaluation of two novel 153Sm bone-seeking agents for radiotherapy of bone metastases: comparison with 153Sm-EDTMP. J Radiother Pract 2015; 14: 252–259.Google Scholar
21. Sparks, R B, Aydogan, B. Comparison of the effectiveness of some common animal data scaling techniques in estimating human radiation dose. Sixth International Radiopharmaceutical Dosimetry Symposium. Oak Ridge, TN: Oak Ridge Associated Universities, 1996: 705–716.Google Scholar
22. Stabin, M G, Siegel, J A. Physical models and dose factors for use in internal dose assessment. Health Phys 2003; 85: 294–310.Google Scholar
23. Stabin, M G, Sparks, R B, Crowe, E. OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005; 46: 1023–1027.Google Scholar
24. Brenner, D J. Effective dose: a flawed concept that could and should be replaced. Br J Radiol 2008; 81: 521–523.Google Scholar
25. ICRP Publication 103. The 2007 recommendations of the international commission on radiological protection. Ann ICRP 2007; 37: 2–4.Google Scholar
26. Bélanger, M J, Krause, S M, Ryan, C et al. Biodistribution and radiation dosimetry of [18F]F-PEB in nonhuman primates. Nucl Med Commun 2008; 29: 915–919.Google Scholar
27. Kesner, A L, Hsueh, W A, Czernin, J et al. Radiation dose estimates for [18F]5-fluorouracil derived from PET-based and tissue-based methods in rats. Mol Imaging Biol 2008; 10: 341–348.Google Scholar
28. Williams, LE. Radiopharmaceuticals: Introduction to Drug Evaluation and Dose Estimation. ISBN 9781439810675, Florida, USA: CRC Press, 2010.Google Scholar